Maternal infection is a cause of spontaneous abortion and preterm labor in humans, but the pathophysiology is unclear. We hypothesized that eicosanoids play an important role in infection-driven pregnancy loss. To investigate this hypothesis, we administered lipopolysaccharide (LPS) to pregnant C3H/HeN mice and found that LPS administration caused fetal death in a dose-dependent fashion. Pretreatment with indomethacin significantly decreased the proportion of fetal death from 83% to < 25% in mice injected with 10 jag of LPS. Also, decidual explants from LPStreated mice produced significantly more inflammatory eicosanoids, including prostaglandins E2 and F2. and thromboxane B2, than controls. We investigated the regulatory mechanisms responsible for increased decidual prostanoid production in response to LPS. Western and Northern blots demonstrated that decidual protein and mRNA levels of a recently recognized highly inducible form of cyclooxygenase, COX-2, were substantially increased in mice treated with LPS. Induction of COX-2 was rapid: mRNA was detected 30 min after LPS injection. In contrast, another form of cyclooxygenase, COX-1, was only minimally induced in response to LPS. Our data indicate that LPS induces decidual prostanoid production via increased COX-2 expression. Since LPS-mediated fetal death is markedly diminished by pretreatment with indomethacin, COX-2-mediated eicosanoid production is likely a key pathophysiologic event in LPS-mediated fetal death. (J. Clin. Invest. 1995. 95:725-731.)
Introduction
Bacterial infections are a recognized cause of fetal loss in animals and man (1) (2) (3) (4) . In the case of gram-negative bacterial infections, fetal loss may result in part from the bacterial cell wall component lipopolysaccharide (LPS). LPS has been (5) and has been implicated as a cause of preterm labor in humans (6, 7) . However, the exact mechanism(s) of LPS-induced pregnancy loss remains unclear. LPS induces a marked inflammatory response that is mediated primarily by the activation of macrophages and the release of cytokines and prostanoids (8) . The inhibition of prostanoid production with cyclooxygenase (COX)' inhibitors attenuates many of the clinical manifestations of bacterial infection (9, 10) .
Cyclooxygenase, also known as prostaglandin H synthase, catalyzes the conversion of arachidonate to prostaglandin H-2 and is a key enzyme in the regulation of prostanoid formation (11) . Two related, yet unique isozymes of cyclooxygenase are known to exist. The first isozyme to be identified and cloned from ovine seminal vesicles is now termed COX-1, or prostaglandin H synthase 1 (12, 13) . Recently another form of cyclooxygenase, referred to as COX-2 or prostaglandin H synthase 2, has been described (14) (15) (16) (17) . Although these enzymes have similar cyclooxygenase and peroxidase activities (18) , they are encoded by different genes and have marked regulatory and functional differences. COX-1 is constitutively expressed in many tissues (11) . Although small increases in COX-1 can occur in response to hormonal or growth factor stimulation (11, 19) , several investigators have failed to show a correlation between the induction of COX-1 mRNA and the induction of prostanoid production in response to mitogens (20, 21) . In sharp contrast, COX-2 is highly inducible during inflammation (22) or in response to LPS (23, 24) .
Since prostanoids mediate the signs and symptoms of gramnegative septic shock (25) , stimulate myometrium (26) , and are capable abortifacients (27) , they are likely to be important mediators of LPS-induced pregnancy loss. In these studies we describe the role of prostanoids in LPS-mediated pregnancy loss and show that intrauterine prostanoid production is associated with an increase in the production of COX-2.
Methods
Animals. C3H/HeN 6-to 8-wk-old virgin female mice were mated with 8-to 12-wk-old C57BI/6 males, and the day of coital plugging was taken as day 0 of pregnancy. This allogeneic mating is well characterized and is not abortion prone. Mice were obtained from Sasco Laboratories (Omaha, NE). Animals had free access to food and water and were exposed to a 12-h light/ 12-h dark cycle. Studies were approved by the University of Utah Institutional Animal Care and Use Committee.
Experimental protocol. Pregnant mice were given a single intraperitoneal injection (1-y1 Mice were killed by cervical dislocation 72 h after the administration of LPS or vehicle, and the status of the fetuses was determined. Gestational sacs were opened, and the fetuses and placentas were evaluated under a X10 dissecting scope. Live pups were distinguished from fetal deaths (which rarely occur in normal pregnancy) and resorptions (which occur early in pregnancy and are often found in normal murine gestations).
Decidual explants. Explants were established using methods that have been previously described and validated (28) . Pregnant mice at days 11-13 of gestation were killed 3 h after injection with 10 jug of LPS or vehicle. After aseptically opening the peritoneal cavity, the pregnant uterus was opened along the antimesenteric border and the gestational sacs and placentas were removed by blunt dissection. Using x 10 magnification, the exposed metrial glands and decidual caps were sharply excised from the uterine wall and cut into fragments of 1 mm3. Explants (30) .
Microsomes were boiled and separated on 10% acrylamide gels in Tris glycine electrophoresis buffer. Prestained molecular weight markers (Bio-Rad Laboratories, Hercules, CA), COX-1 protein (purified from ram seminal vesicles; Cayman Chemical Co., Ann Arbor, MI), and purified murine COX-2 protein (Cayman Chemical Co.) were run on each gel. After separation, protein was transblotted to nitrocellulose (Bio-Rad Laboratories). Blots were blocked in a solution containing 3% non-fat dry milk and incubated in the presence of anti-COX-1 (diluted 1:500) or anti-COX-2 (diluted 1:500) antibodies for 2 h at room temperature. The anti-COX-l antibody was generated in rabbits against ram seminal vesicle COX-1; the anti-COX-2 antibody was generated in rabbits against the 18-amino acid COOH terminus of COX-2 (23) . Antibodies were kind gifts of Dan Hwang (Louisiana State University, Baton Rouge, LA). Blots were incubated with biotinylated goat anti-rabbit IgG (diluted 1:3,000; Bio-Rad Laboratories) followed by streptavidin-biotinylated alkaline phosphatase (diluted 1:3,000). Color development was in alkaline phosphatase color reagents (Bio-Rad Laboratories).
Northern blot analysis. Total cellular RNA was prepared from murine deciduae by the acid guanidinium thiocyanate-phenol-chloroform method of Chomczynski and Sacchi (31 ). RNA was similarly extracted from cultured NIH3T3 cells (a murine fibroblast cell line; American Type Culture Collection, Rockville, MD) stimulated with 10 jug/ml LPS in RPMI containing 3% FCS for 6 h, for use as a positive control. indomethacin were as effective as higher doses in decreasing the rate of LPS-induced fetal death, suggesting that the effect was a direct consequence of cyclooxygenase inhibition. In vivo absorption of indomethacin was confirmed by using two routes of administration and demonstrating a reduction in uterine PGE2 production in response to LPS in mice treated with indomethacin (see the following discussion).
Next, we used cultures of murine decidual explants to study the effect of in vivo LPS exposure on uterine prostanoid production. Fig. 2 shows the means and standard errors for PGE2 production by decidual explants taken from mice killed 3 h after injection with 10 tg of LPS or vehicle. On each day of explant culture, the mean decidual production of PGE2 after LPS injection was significantly greater than that of controls, and the increased mean production of PGE2 persisted through day 3 of culture (P < 0.01). Fig. 3 depicts the means and standard errors for uterine explant PGE2 production in mice pretreated with indomethacin.
Indomethacin at both 2.5 ,ug and 35 qg/d effectively blocked uterine PGE2 production in response to LPS administration. These data indicate that treatment with indomethacin inhibited prostaglandin biosynthesis in the decidua.
Since PGE2 has many effects, some of which are proinflammatory and some of which are antiinflammatory, we tested additional decidual explant cultures for the production of PGF2, and TXB2 (a stable thromboxane A2 metabolite) as well as PGE2. These eicosanoids are considered to be primarily proinflammatory. The means and standard errors for prostanoid production by decidual explants in the first 24 h of culture taken from mice killed 3 h after injection with 10 Mug of LPS or vehicle are shown in Fig. 4 . Results for PGF2, and TXB2 were similar to those for PGE2. Explants taken from mice treated with LPS exhibited a twofold and 60% increase in PGF2z, and TXB2 production, respectively, compared with controls (P < 0.01).
We then sought to investigate the regulatory mechanisms responsible for increased uterine prostanoid production in response to LPS. To test the hypothesis that the induction of COX, specifically the highly inducible isotype COX-2, might increase uterine prostaglandin synthesis, we characterized decidual protein and mRNA production of COX-1 and COX-2 in LPS-treated mice. Fig. 5 shows a representative Western blot prepared using decidual microsomal proteins taken from animals that were killed at serial time points after injection with 10 Mig of LPS or vehicle and detected with an antibody against COX-2. COX-2 was present at low levels in decidua from untreated and PBStreated mice. However, COX-2 was increased up to sixfold in deciduae from three animals treated with LPS, as measured by densitometry. This increase in COX-2 protein was most profound 2-4 h after LPS exposure (four-to sixfold increase), and levels returned to basal amounts 8 h after LPS administration in all cases. COX-2 was always detected as a single band in murine deciduae. We recognize that others have observed a doublet (23) and speculate that COX-2 may be processed differently in gestational tissues than in other cell types.
Protein ascertained with the antibody against COX-1 was detected at low levels in deciduae taken from untreated animals as well as at all time points after treatment with PBS. In contrast to COX-2, markedly increased levels of decidual COX-1 were not detected after LPS injection. In deciduae from three mice a-f Replicates of six were used for each experiment. PGE2 production by explants from LPS-treated mice was greater than that by explants from PBS-treated mice on all 3 d (P < 0.01; Mann-Whitney U test).
treated with LPS, COX-1 levels were unchanged from untreated or PBS-treated mice at 1, 6, and 8 h after injection. In each animal, COX-1 levels were slightly increased at 2 and 4 h after LPS administration. However, the increases were modest and averaged 40%. The anti-COX-1 antibody cross-reacted with COX-2, precluding definitive conclusions about COX-1 expression.
A representative Northern blot of decidual RNA hybridized with a partial cDNA for COX-2 is depicted in Fig. 6 . COX-2 mRNA was not detected at any time point in deciduae taken from four PBS-injected animals. However, in LPS-treated ani- DAY OF EXPLANT CULTURE Figure 3 . PGE2 production by decidual explants taken from mice pretreated with indomethacin. Production of PGE2 (mean+SEM) over 24 h by murine decidual explants taken from mice that were sacrificed 3 h after injection with 10 ,ug of LPS or PBS. Replicates of six were used for each experiment. PGE2 production by explants from LPS-treated mice that were pretreated with indomethacin (35 ,ug or 2.5 4g/d) was similar to controls. transcript), but was not detected in decidual RNA samples from either PBS-or LPS-treated animals using this technique (data not shown).
Discussion
Our data show that LPS induces a substantial increase in decidual COX-2 mRNA and protein and suggest that this mechanism plays an important role in LPS-mediated fetal death. In 1972, Skarnes and Harper first associated LPS-induced abortion with prostaglandins (35) . They demonstrated an increase in intrauterine PGF concentrations in pregnant mice treated with LPS and showed that systemic administration of PGE2 and PGF2e, resulted in murine fetal death (35) . In their experiments, pretreatment with 10 jig (2 mg/kg) of indomethacin blocked fetal expulsion in response to LPS. However, indomethacin did not decrease the rate of fetal death after LPS administration, leading these investigators to conclude that substances other than prostaglandins were responsible for LPSinduced fetal death (35) . In contrast, we have demonstrated that murine fetal loss in response to LPS is significantly blocked by indomethacin. Possible reasons for differences between their results and our data include the short duration of indomethacin therapy (2-3 h prior to LPS injection), the late gestational age of experimentation (16 d) , and the lack of confirmation of prostaglandin blockade in the previous study (35) .
The pathophysiology of prostanoid-mediated fetal death is uncertain. PGE2 and other eicosanoids can cause myometrial contractions (26) , which could lead to ischemia in the decidua, placenta, and fetus. Other potential mechanisms are decreased perfusion of gestational tissues secondary to increased vascular permeability caused by prostaglandins, or platelet aggregation and vasoconstriction due to thromboxanes (25) . LPS may also exert systemic effects on the maternal vasculature that are pathogenic to the fetus. We speculate that prostaglandins may be more important mediators of LPS-induced fetal death than thromboxane, since prostaglandin production in response to LPS was enhanced to a relatively greater degree. Experiments using specific prostanoid inhibitors may help to define further the pathogenic role of each eicosanoid.
It is likely that compounds other than prostanoids contribute to LPS-induced fetal loss, since pretreatment with indomethacin only partially blocked LPS-induced fetal death. Candidates include inflammatory cytokines such as tumor necrosis factors and interleukin-1. These potent molecules mediate many of the biological effects of LPS (36) , and both cause murine fetal death in a dose-dependent fashion (37, 38) . Other immune effectors that are induced by LPS and may directly or indirectly harm the fetus are platelet-activating factor, interferon-y, and products of lipoxygenase activity (39) .
Our data show that in vivo decidual prostanoid production in response to LPS is associated with an increase in the levels of COX-2 mRNA and protein. The induction of COX-2 was rapid, with detectable levels of COX-2 mRNA noted 0.5 h after LPS administration. Elevations in COX-2 were also short lived: COX-2 protein levels returned to those of untreated animals by 8 h, and COX-2 mRNA was undetectable at 16 h after exposure to LPS. These data are consistent with several recent reports about the rapid inducibility of COX-2 in a variety of tissues ( 15, 23, 24, 40, 41) . COX-1 mRNA was not detected in deciduae from LPS-injected mice, and COX-1 protein levels were stable or only minimally elevated in response to LPS. Since the anti-COX-l antibody also recognizes COX-2, albeit to a much lesser degree (23) , it is unclear whether the slight increase observed in COX-1 protein in LPS-treated mice is due to an actual increase in COX-1 or to cross-reactivity with COX-2. Even if this represents a true elevation of COX-1, such a small induction is unlikely to account for the increase in PGE2 production in uterine decidua and metrial glands after LPS injection.
Since COX-l is constitutively expressed in many tissues, it has been purported to be a "housekeeping gene" responsible for prostaglandin production and necessary for normal cellular processes (42) . Conversely, it has been hypothesized that COX-2 is the "inflammatory enzyme" that causes prostaglandin production involved in inflammation and mitogenesis (42) . Our data are certainly consistent with such a model.
It is possible that enzymes other than COX-2 are responsible for some of the increased decidual prostanoid production in response to LPS. LPS may induce phospholipases that are important upregulators of prostanoid production. Our studies do not address the issue of whether or not COX-2 enzymatic activity is increased in response to LPS. Thus, we recognize that phospholipases or other enzymes may contribute to LPS-induced prostanoid production in gestational tissues.
It is unclear which uterine cell type is responsible for the elaboration of COX-2 and PGE2 in response to LPS. A likely candidate is the uterine macrophage. The murine metrial gland is rich in macrophages (43), and macrophages have been shown to induce COX-2 in response to LPS (23, 24, 44) . Moreover, although both glandular and stromal decidual cells are capable of eicosanoid production (45), studies using flow cytometry have shown decidual macrophages to have the highest rates of PGF2, and PGE2 biosynthesis in vitro (46) .
The treatment of mice with LPS provides an animal model with which to study the effects of acute LPS-induced inflammatory injury during pregnancy. The pathophysiology of maternal infection is relevant not only to fetal death, but also to other adverse pregnancy outcomes associated with infection, including preterm labor and premature rupture of membranes. Our results indicate that the induction of COX-2 is a key mediator of LPS-induced fetal death and is likely responsible for pathologic events such as preterm labor, premature rupture of membranes, and intrauterine infection, which are known to be associated with elevated prostanoid levels (47, 48) .
Defining the physiologic roles for each form of COX will provide insight into many processes in reproductive biology. An exciting aspect of such research is the potential for the development of selective antagonists for each of these isoenzymes (42, 50) . Specific COX inhibitors would have promise as therapeutic agents in obstetrics, for example, as a treatment for preterm labor. Although clinically evident infection is a contraindication for tocolysis, there is subclinical, histologic evidence of inflammation or inflammatory changes in gestational tissues in over half of deliveries prior to 32-wk gestation (1) . Perhaps because of their antiinflammatory properties as well as their inhibition of prostaglandins, nonsteroidal drugs appear to be effective agents for the treatment of idiopathic preterm labor (50, 51) . However, their use is severely limited by untoward fetal effects (52, 53) . It has been suggested that the antiinflammatory actions of cyclooxygenase inhibitors are due to the inhibition of COX-2, whereas unwanted side effects are due to the inhibition of the constitutively expressed COX-1 (54) . Thus, a selective antagonist for COX-2 merits investigation as a potentially safe and effective treatment for idiopathic preterm labor.
